| Recruiting | 3 | 149 | Europe | Multivirus (CMV, EBV, AdV)-specific T cells | Prof. Tobias Feuchtinger, European Commission, Simbec-Orion Group Ltd, Merthyr Tydfil, UK, Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany, Leiden University Medical Center, LUMC, Leiden, The Netherlands, Centre Hospitalier Universitaire de Nancy, CHU, Vandoeuvre-Lès-Nancy, France, Ghent University Hospital, UZG, Ghent, Belgium, Ospedale Pediatrico Bambino Gesù, OPBG, Rome, Italy, Newcastle University, UNEW, Newcastle, UK, Vall d'Hebron Institute of Oncology (VHIO) and Banc de Sang I Teixits (BST), Barcelona, Spain | AdV Infection, EBV Infection, CMV Infection, Stem Cell Transplant Complications | 06/24 | 12/24 | | |
| Recruiting | 1/2 | 55 | Europe | venetoclax + azacitidine +/- donor lymphocyte infusion, venclyxto, vidaza | Groupe Francophone des Myelodysplasies, AbbVie | MDS, AML | 09/25 | 03/26 | | |
NCT05782127: Oral Azacitidine Combined with Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes |
|
|
| Recruiting | 1/2 | 36 | Europe | Onureg + Venetoclax, CC-486 + ABT-199 | Groupe Francophone des Myelodysplasies, Bristol-Myers Squibb, AbbVie | Untreated Myelodysplastic Syndrome | 11/25 | 11/28 | | |
NCT05181735: Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA |
|
|
| Recruiting | 1/2 | 150 | Europe | Luspatercept Injection [Reblozyl], ACE-536, Eprex, Epoietin alfa | Groupe Francophone des Myelodysplasies, Celgene | MDS, Myelodysplastic Syndromes | 05/27 | 11/27 | | |
